Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 9c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $24.51 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• Quaint Oak Bancorp, Inc. (QNTO) Declares $0.04 Quarterly Dividend; 1.1% Yield
• Active options: NVDA TSLA AAPL MU MSFT SPCX NFLX INTC AMZN META